Conditioning Regimens Produce Similar Long-Term Outcomes in Newly Diagnosed Multiple Myeloma
Conditioning with MEL200 or BUMEL produced similar outcomes at 7 years.
Multiple Myeloma
Treatment Advances Have Improved Multiple Myeloma Mortality in the US
Researchers sought to determine the mortality trends for patients with multiple myeloma over the past few decades.
Access to Trials of CAR T-Cell Therapy or Bispecific Antibodies May Vary by Race
Black patients with multiple myeloma may not have equitable access to clinical trials of CAR T-cell therapy or bispecific antibodies.
Increased Risk of MGUS Among World Trade Center Rescue and Recovery Workers
Researchers sought to determine if the risk of developing MGUS was present in a more heterogeneous population of World Trade Center rescue and recovery workers.
Belantamab Mafodotin Yields Good Response Rate in Patients With Relapsed, Refractory Multiple Myeloma
Researchers sought to determine whether belantamab mafodotin would be a viable option for treating patients with relapsed/refractory multiple myeloma
Lower Risk of Smoldering Multiple Myeloma Progression Among African Americans
Researchers sought to determine whether there were differences in rates of progression of smoldering multiple myeloma in African American patients.
D-Rd Appears to Improve Long-Term Outcomes in Newly Diagnosed, Transplant-Ineligible Myeloma
Researchers sought to determine whether adding daratumumab to lenalidomide and dexamethasone would improve outcomes in patients with newly diagnosed, transplant-ineligible MM.
Quadruplet Therapy Shows Promising Results as Salvage Therapy for Relapsed/Refractory Multiple Myeloma
Researchers sought to determine whether adding ixazomib to daratumumab, pomalidomide, and dexamethasone would be a treatment option in patients with R/R MM.
Isatuximab Provides “Clinically Meaningful” OS Benefit in Rel/Ref Multiple Myeloma
Final results from ICARIA-MM support isatuximab plus pomalidomide and dexamethasone as a standard of care for relapsed/refractory multiple myeloma, according to researchers.
Certain Blood Cancer Patients Do Not Seroconvert After a Third COVID-19 Vaccine Dose
Seroconversion rates were low for patients receiving anti-CD20 therapy, CAR T-cell therapy, and transplants, as well as CLL patients taking ibrutinib.
- Loading...
Loading...
Next post in General Hematology
Loading... 
Loading...